TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9128029

Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg (2 ml of lidocaine 2%) added to 180 mg of propofol (18 ml)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Normal saline (2 ml) added to 180 mg of propofol (18 ml)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg premixed with 180 mg propofol
Number of subjects: 106
Study: 7946254

Group type: EXPERIMENTAL
Intervention: Choral responding and student-to-student responding in small groups
Number of subjects: 24
Study: 3253231

Group type: EXPERIMENTAL
Intervention: Low-intensity continuous exercise training (CE; 40 min at 50% VO2peak, 3 days/week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise training (IE: 10 x 2 min at VO2peak, 3 days/week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31758216

Group type: EXPERIMENTAL
Intervention: Educational session on prescribing skills
Number of subjects: 34
Study: 29631564

Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine (group T)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.9% isotonic saline (group C)
Number of subjects: 70
Study: 27040503

Group type: EXPERIMENTAL
Intervention: n‐3 PUFAs, 1 g three times a day for 18 months
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study: 25378225

Group type: EXPERIMENTAL
Intervention: 5-grass pollen sublingual tablet
Number of subjects: 849
Study: 22337597

Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the right DLPFC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS of the left DLPFC
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study: 20228976

Group type: EXPERIMENTAL
Intervention: Polylactic acid barrier
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Collagen membrane
Number of subjects: 30
Study: 18525396

Group type: EXPERIMENTAL
Intervention: Darbepoetin-alpha (1.5 microg/Kg every 20 days for 3 months) plus iron orally
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo plus iron orally
Number of subjects: 41
Study: 15671806

Group type: EXPERIMENTAL
Intervention: 1 g of azithromycin
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: 2 g of metronidazole +/‐ 500 mg of ciprofloxacin
Number of subjects: 363

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 363
Study: 12353340

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg, increased to 20 mg after 8 weeks
Number of subjects: 157

Group type: COMPARATOR
Intervention: Simvastatin 10 mg, increased to 20 mg after 8 weeks
Number of subjects: 157
Study: 10577635

Group type: EXPERIMENTAL
Intervention: Conventional antihypertensive drugs (atenolol 50 mg, metoprolol 100 mg, pindolol 5 mg, or hydrochlorothiazide 25 mg plus amiloride 2.5 mg daily)
Number of subjects: 6614

Group type: COMPARATOR
Intervention: Newer antihypertensive drugs (enalapril 10 mg or lisinopril 10 mg, or felodipine 2.5 mg or isradipine 2‐5 mg daily)
Number of subjects: 6614

Group type: EXPERIMENTAL
Intervention: Conventional antihypertensive drugs
Number of subjects: 6614

Group type: COMPARATOR
Intervention: Newer antihypertensive drugs
Number of subjects: 6614
Study: 8741162

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1727996

Group type: EXPERIMENTAL
Intervention: Comprehensive prenatal care
Number of subjects: 428

Group type: COMPARATOR
Intervention: Standard prenatal care
Number of subjects: 428
Study: 2987139

Group type: EXPERIMENTAL
Intervention: Activated charcoal (50 g) given 5 min after dextropropoxyphene hydrochloride (130 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Activated charcoal (50 g) followed by 12.5 g at 6 h intervals
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acidification of urine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alkalinization of urine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Urinary pH influence
Number of subjects: 6
Study: 31044492

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg daily
Number of subjects: 84

Group type: COMPARATOR
Intervention: Oral tetracycline 250 mg bd and topical benzoyl peroxide 2.5%
Number of subjects: 84
Study: 29135357

Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride (PH)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (Control Group)
Number of subjects: 71
Study: 24480761

Group type: EXPERIMENTAL
Intervention: Reciprocating saw
Number of subjects: 20

Group type: COMPARATOR
Intervention: Piezosurgery device
Number of subjects: 20
Study: 22957501

Group type: COMPARATOR
Intervention: Standard best practice care (SBP)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Standard best practice care (SBP+RM)
Number of subjects: 44
Study: 20456303

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 17346763

Group type: EXPERIMENTAL
Intervention: Rods (0.002‐0.2 Trolands)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cones (200 Trolands)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rods and Cones (2‐20 Trolands)
Number of subjects: 0
Study: 15626549

Group type: EXPERIMENTAL
Intervention: Public Health Dose (17.5 kcal/kg/week, 3 or 5 days/week)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Low Dose (7.0 kcal/kg/week, 3 or 5 days/week)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (3 days/week flexibility exercise)
Number of subjects: 80
Study: 12081121

Group type: EXPERIMENTAL
Intervention: L1 group (lower limbs in neutral position when analgesic level reached L1 dermatome)
Number of subjects: 90

Group type: COMPARATOR
Intervention: T6 group (lower limbs in neutral position when analgesic level reached T6 dermatome)
Number of subjects: 90
Study: 10208996

Group type: EXPERIMENTAL
Intervention: Corrected TIMI frame count (CTFC) measured at 90 minutes after thrombolytic administration.
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: Corrected TIMI frame count (CTFC) as an independent predictor of in-hospital mortality.
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: Corrected TIMI frame count (CTFC) in patients with TIMI grade 3 flow.
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: Corrected TIMI frame count (CTFC) in patients with TIMI grade 3 flow (CTFC ≤40).
Number of subjects: 1248
Study: 8004854

Group type: EXPERIMENTAL
Intervention: Referral to nursing, social work, physiotherapy, occupational therapy, or dietary services for potential discharge planning in Hospital A
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Referral to nursing, social work, physiotherapy, occupational therapy, or dietary services for potential discharge planning in Hospital B
Number of subjects: 421

Group type: COMPARATOR
Intervention: Control group in Hospital A
Number of subjects: 421

Group type: COMPARATOR
Intervention: Control group in Hospital B
Number of subjects: 421
Study: 2599668

Group type: EXPERIMENTAL
Intervention: Keto-analogues (200 mg/kg/d) with low-protein diet (0.4 g/kg/d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Keto-analogues (200 mg/kg/d) with normal protein diet (1 g/kg/d)
Number of subjects: 15
Study: 30920411

Group type: EXPERIMENTAL
Intervention: At least twice daily screening led by respiratory therapists
Number of subjects: 155

Group type: COMPARATOR
Intervention: Once daily screening led by respiratory therapists
Number of subjects: 155
Study: 28282792

Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 26397992

Group type: EXPERIMENTAL
Intervention: Shennan definition of bronchopulmonary dysplasia
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: National Institutes of Health Workshop definition
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Physiologic definition after a room-air challenge
Number of subjects: 765

Group type: COMPARATOR
Intervention: Workshop definition
Number of subjects: 765

Group type: COMPARATOR
Intervention: Physiologic definition
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Modified Shennan definition
Number of subjects: 765

Group type: COMPARATOR
Intervention: High-flow nasal cannula management
Number of subjects: 765
Study: 23297184

Group type: EXPERIMENTAL
Intervention: Spiritual counselor/clergy consultation
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Openness to seeking help from spiritual counselors/clergy
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Primary care provider openness
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Psychiatrist openness
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Other mental health provider openness
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: VA providers asking about spiritual support
Number of subjects: 761
Study: 21659488

Group type: COMPARATOR
Intervention: Sprint exercise (30-s Wingate test) in fasting group (n = 7, C)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sprint exercise (30-s Wingate test) after glucose ingestion (n = 8, G)
Number of subjects: 15
Study: 18470779

Group type: EXPERIMENTAL
Intervention: Treatment program based on evidence‐based treatments (EBTs) for disruptive behavior problems
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (delayed implementation)
Number of subjects: 117
Study: 16508257

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional yogurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both probiotic and conventional yogurt
Number of subjects: 33
Study: 12722967

Group type: EXPERIMENTAL
Intervention: Azelastine eyedrops
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10925331

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 42

Group type: COMPARATOR
Intervention: Small-molecule IIb/IIIa inhibitors (eptifibatide or tirofiban)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 8882035

Group type: EXPERIMENTAL
Intervention: Esophageal scintigraphy using a semisolid orally ingested bolus
Number of subjects: 301
Study: 8226583

Group type: EXPERIMENTAL
Intervention: Fenfluramine (1.5 mg/kg per day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.4 mg/kg per day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 3536644

Group type: EXPERIMENTAL
Intervention: Ensure, a defined formula dietary supplement
Number of subjects: 122
Study: 31498112

Group type: EXPERIMENTAL
Intervention: Selective intracoronary hypothermia (SIH) during primary percutaneous coronary intervention (PPCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 30088077

Group type: EXPERIMENTAL
Intervention: 2% lidocaine plus adrenaline
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2% tetracaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 4% articaine plus adrenaline
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (NaCl)
Number of subjects: 90
Study: 26635402

Group type: EXPERIMENTAL
Intervention: E-CPR
Number of subjects: 3756

Group type: COMPARATOR
Intervention: C-CPR
Number of subjects: 3756
Study: 24634333

Group type: EXPERIMENTAL
Intervention: Continue 24 h more CPD
Number of subjects: 20

Group type: COMPARATOR
Intervention: Discontinue CPD (control)
Number of subjects: 20
Study: 22699797

Group type: EXPERIMENTAL
Intervention: PASCET-PI (Primary and Secondary Control Enhancement Therapy-Physical Illness)
Number of subjects: 41

Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 41
Study: 19940774

Group type: EXPERIMENTAL
Intervention: Early start of exercise training (EG) - low-intensity exercise training two times a week for 4 weeks before entering ordinary exercise training of moderate-to-high intensity (phase 2b)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Delayed start control group (CG) - entered phase 2b directly after 4 weeks of delay
Number of subjects: 39
Study: 18353212

Group type: EXPERIMENTAL
Intervention: recombinant human PEGIHN‐beta‐1a (n = 13)
Number of subjects: 21

Group type: COMPARATOR
Intervention: PEGIHN‐beta‐1a plus ribavirin (RBV) (n = 8)
Number of subjects: 21
Study: 16429182

Group type: COMPARATOR
Intervention: Group 1 (no demineralizing agent)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Group 2 (35% phosphoric acid, for 15 s)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Group 3 (17% EDTA solution, pH 7, for 3 min)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Group 4 (24% EDTA gel, pH 7, for 4 min)
Number of subjects: 56
Study: 12360101

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg bodyweight)
Number of subjects: 534

Group type: COMPARATOR
Intervention: Healthy controls (370 individuals)
Number of subjects: 534
Study: 10353855

Group type: EXPERIMENTAL
Intervention: Rimantadine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7499620

Group type: EXPERIMENTAL
Intervention: Quality of care as perceived by carers through focused interviews and questionnaires
Number of subjects: 41
Study: 1936109

Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN) during chemotherapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Spontaneous oral intake only (Control)
Number of subjects: 33
Study: 7287241

Group type: EXPERIMENTAL
Intervention: Amiloride (5 mg) and Tienilic acid (250 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Triamterene (100 mg) and Tienilic acid (250 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Amiloride (10 mg) and Tienilic acid (250 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Triamterene (200 mg) and Tienilic acid (250 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tienilic acid (250 mg)
Number of subjects: 18
Study: 31261168

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of phenylephrine (P group)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of norepinephrine (N group)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No vasopressor (C group)
Number of subjects: 51
Study: 29028556

Group type: EXPERIMENTAL
Intervention: Buspirone (45mg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intranasal methamphetamine (0, 15, and 30mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 26880253

Group type: EXPERIMENTAL
Intervention: Handheld fan and exercise advice
Number of subjects: 49

Group type: COMPARATOR
Intervention: Advice alone (control)
Number of subjects: 49
Study: 24981955

Group type: EXPERIMENTAL
Intervention: Antifungal treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22088800

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of 1 million autologous cardiac stem cells (CSCs) at a mean of 113 days after surgery.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 23
Study: 19702811

Group type: EXPERIMENTAL
Intervention: Childbirth education class
Number of subjects: 40
Study: 17476007

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg)
Number of subjects: 3889

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3889
Study: 15008866

Group type: EXPERIMENTAL
Intervention: 2% hydroquinone
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.025% tretinoin
Number of subjects: 50
Study: 11282782

Group type: EXPERIMENTAL
Intervention: Denture use
Number of subjects: 76
Study: 10684069

Group type: EXPERIMENTAL
Intervention: Methylphenidatum
Number of subjects: 70

Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nikethamidi
Number of subjects: 70
Study: 7701971

Group type: EXPERIMENTAL
Intervention: Cocaine-dependent patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alcohol-dependent patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-drug-dependent controls
Number of subjects: 30
Study: 3109144

Group type: EXPERIMENTAL
Intervention: Tetracycline (250 mg four times a day for 10 days)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Penicillin (250 mg four times a day for 10 days)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Erythromycin (250 mg four times a day for 10 days)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High-dose intravenous penicillin (20 million U a day for 10 days)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intramuscular benzathine penicillin (7.2 million U)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intravenous penicillin G (20 million U a day for 10 days)
Number of subjects: 39
Study: 29705470

Group type: EXPERIMENTAL
Intervention: Black cumin oil applied by rubbing to knees 3 times a week for 1 month
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine prescription (control group)
Number of subjects: 60
Study: 26965031

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 235
Study: 24440931

Group type: EXPERIMENTAL
Intervention: Cinitapride (1 mg)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Domperidone (10 mg)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Cinitapride
Number of subjects: 383

Group type: COMPARATOR
Intervention: Domperidone
Number of subjects: 383
Study: 22345157

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18950374

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 79
Study: 16011640

Group type: EXPERIMENTAL
Intervention: Cerana inserts
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SonicSys inserts
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: beta‐quartz inserts
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SonicSys inserts in dentine‐bordered specimens
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IPS Empress inserts (Cerana, SonicSys enamel)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SonicSys inserts in deep proximal cavities
Number of subjects: 60
Study: 12873927

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5%
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ropivacaine 0.5%
Number of subjects: 14
Study: 10578770

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for 4 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obstacles to exclusive breastfeeding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community messages to promote EBF
Number of subjects: 0
Study: 9254522

Group type: EXPERIMENTAL
Intervention: CAG repeat expansion search in patients with schizophrenia and essential tremor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Locus HS0073
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 0
Study: 1895011

Group type: EXPERIMENTAL
Intervention: Self‐questioning strategy with self‐instructional training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard instruction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Generalization induction condition with informed training and self‐instructional training techniques
Number of subjects: 60
Study: 6411479

Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment (30 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 9
Study: 31102938

Group type: EXPERIMENTAL
Intervention: Sodium selenite therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 28379902

Group type: EXPERIMENTAL
Intervention: Cangrelor (Kengreal) administered as an intravenous infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cangrelor (Kengreal) as bridging therapy
Number of subjects: 0
Study: 27100174

Group type: EXPERIMENTAL
Intervention: Breast cancer screening (HIP trial)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Breast cancer screening (Age trial)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Breast cancer screening (TCT)
Number of subjects: 2
Study: 25138802

Group type: EXPERIMENTAL
Intervention: Third-wave cognitive therapy (n=22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Mentalisation-based treatment (n=22)
Number of subjects: 44
Study: 23173831

Group type: EXPERIMENTAL
Intervention: n-3 PUFA (3g daily) for 5 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19067776

Group type: EXPERIMENTAL
Intervention: Moderate-intensity lifestyle intervention (6 sessions/10 weeks)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Low-intensity lifestyle intervention (3 sessions/4 weeks)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 152
Study: 17254907

Group type: EXPERIMENTAL
Intervention: Maximal grip strength trials
Number of subjects: 30

Group type: COMPARATOR
Intervention: Submaximal grip strength trials
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Slope of the force‐generation phase
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Slope of the force‐decay phase
Number of subjects: 30
Study: 15146330

Group type: EXPERIMENTAL
Intervention: L -5-Hydroxytryptophan (2 mg/kg per day) administered at bedtime for 20 consecutive days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 45
Study: 11766248

Group type: EXPERIMENTAL
Intervention: Neostigmine (various doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omitting reversal of neuromuscular block
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Train-of-four ratio > or = 0.9
Number of subjects: 0
Study: 9526930

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg plus ondansetron 4 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Droperidol plus saline (Control)
Number of subjects: 160